TIC is a growth-hormone-secretagogue blend combining GHRH-pathway and GHRP-pathway peptides — the
one blend in this batch whose combination rationale has a clear, well-established mechanistic basis.
Composition.
Tesamorelin (a stabilised GHRH analog), Ipamorelin (a selective GHRP / ghrelin-receptor
agonist), and CJC-1295 (a long-acting GHRH analog). See each component monograph for details.
Combination rationale.
This is the textbook GH-secretagogue pairing logic: a GHRH analog (tesamorelin / CJC-1295) and
a GHRP (ipamorelin) act on two different receptors in the GH-release pathway, and the research
literature reports that combining the two pathways produces a larger, more physiological GH pulse
than either alone. Including both tesamorelin and CJC-1295 means two GHRH analogs are present, which
is somewhat redundant on the GHRH side — a fair caveat — while ipamorelin supplies the
complementary GHRP arm.
What the research shows.
The GHRH-plus-GHRP synergy is well described at the single-pathway level, but this specific
three-peptide product has no dedicated trial. Tesamorelin individually is an approved drug (for
HIV-associated lipodystrophy); ipamorelin and CJC-1295 are research peptides. The synergy rationale
is sound; the specific blend's effects are not independently characterised.
Human clinical trial data.
No human clinical trial has established administration parameters for the TIC blend; VialTalk does not provide community-sourced dosing.
Quality & sourcing notes.
A blend COA should confirm all three peptides by identity and amount and state the ratio — with two
GHRH analogs plus a GHRP, verifying that all three are actually present and correctly proportioned
is the key check. Per-component mass-spec identity is the standard.
*Research-use note: This monograph is an educational summary of the published research literature.
TIC is a vendor blend; tesamorelin is an approved drug while the other components are research
compounds — all are described here for research context only. Nothing here is medical advice or a
usage recommendation.*
